Selecta Biosciences is a clinical-stage biopharmaceutical company developing targeted immunotherapies and vaccines that are designed to modulate immune responses to treat and prevent disease. Selecta’s proprietary Synthetic Vaccine Particle (SVP™) platform has the potential to create a new paradigm in immunology and may enable a novel approach for selectively targeting the immune system to effectively and safely treat and prevent rare and serious diseases...View more »
|View all press releases »|
|View all events »|
Stern Investor Relations, Inc.
Phone: 1 212 362 1200
|Data provided by Nasdaq. Minimum 15 minutes delayed.|